Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

Boston Scientific has recently reported the results of the Optical Coherence Tomography Drug Eluting ... of this stent platform in larger groups of patients. Elixir Medical (CA, USA) reported ...

Non-drug eluting devices, such as bare-metal stents, catheters, and implantable medical devices, are widely used in procedures where drug elution is not necessary, or where a more mechanical or ...

WASHINGTON--(BUSINESS WIRE)--Elixir Medical, a developer of disruptive ... to contemporary Resolute Onyx ™ zotarolimus drug-eluting stent (DES) for target lesion failure (TLF) in complex patient ...

Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior ...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final two rounds ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD). The data, which was presented as a ...

TCT discussant Joanna Wykrzykowska, MD, PhD, of University Medical Center Groningen in the Netherlands, said she was "very ...

The DynamX [Image courtesy of Elixir Medical] Elixir Medical announced positive data ... Data highlighted the success of ...

In patients with dissections, perforations that could not be conservatively managed, for which coronary drug-eluting stents (DES) or sacrificing the ... Tyrocore material, used in the MOTIV BVS (Reva ...